ArticleDermatology and therapy2026
Current Challenges in Atopic Dermatitis: An Italian Delphi Consensus with a Special Focus on Moderate Disease.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAtopic dermatitis (AD) is a chronic, inflammatory skin disease clinically characterized by eczematous lesions and severe itch, significantly affecting the patients' quality of life. AD is classified as mild, moderate, or severe according to the extent and severity of these lesions. While therapeutic protocols for mild and severe AD are well-defined, the moderate stage represents a clinical 'gray zone' characterized by inconsistent management. It is frequently mismanaged, oscillating between undertreatment and the indiscriminate use of traditional systemic therapies. The moderate stage of AD requires a tailored approach to maximize topical treatments efficacy, avoid the side effects of systemic drugs, while remaining ready to escalate therapy if needed.
methodsAn Italy-based, expert-Delphi consensus was used to: (1) reach a consensus on moderate AD classification criteria; (2) characterize the disease-specific burden in these patients; (3) identify key elements and concerns in moderate AD treatment; and (4) identify the therapeutic and management-related unmet needs of this subset of patients.
resultsAgreement was reached for 26 final statements, which included highlighting a significant disease burden also for patients with moderate AD.
conclusionsThe findings underscore a misalignment between the actual disease burden of moderate AD and current regulatory reimbursement criteria. In Italy, the restricted access to innovative systemic therapies for this specific patient population represents a critical healthcare gap.
Indexed as
Identifiers
42909837What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.